Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%

Journal of Drugs in Dermatology

Volumn 12, Issue 9, 2013, Pages 1004-1008

  Plaum, Stefan ^a   Verma, Amit ^a   Fleischer Jr , Alan B ^a   Olayinka, Babajide ^a   Hardas, Bhushan ^a  

^a Merz Pharmaceuticals LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAFTIFINE;

ADULT; AGED; ARTICLE; BODY MASS; BODY PIERCING; CLINICAL ARTICLE; CREAM; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; OPEN STUDY; OUTCOME ASSESSMENT; STRATUM CORNEUM; TINEA CRURIS; TINEA PEDIS;

ADMINISTRATION, CUTANEOUS; ADULT; ALLYLAMINE; ANTIFUNGAL AGENTS; BODY MASS INDEX; CHEMISTRY, PHARMACEUTICAL; FEMALE; GELS; HUMANS; MALE; OINTMENTS; SKIN; SKIN ABSORPTION;

EID: 84883396554     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Noble S, Forbes RC, Stamm P. Diagnosis and management of common tinea infections. Am Fam Physician. 1998; 58(1):163-74.
2. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician. 2002;65(10):2095-102.
3. Vander Straten MR, Hossain MA, Ghannoum MA. Cutaneous infections, dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin N Am. 2003;17(1):87-112.
4. Pray WS, Pray J. Tinea cruris in men: Bothersome but treatable. U.S. Pharmacist (Internet). 2005 Sept [cited 2010 Jul 02];30(9):[about 7 p.]. Available from: http://www.medscape.com/viewarticle/512992.
5. Panackal AA, Halpern EF, Watson AJ. Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004. Int J Dermatol. 2009;48(7):704-12.
6. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50(5):748-52.
7. Blass B. How to detect and treat tinea pedis. Podiatry Today [Internet]. 2005 Jan [cited 2010 Jul 02];18(1):[about 6 p.]. Available from: http://www.podiatrytoday.com/article/3472.
8. Hasan M, Fitzgerald M, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy. 2004;2:5.
9. Wiederkehr M. Tinea cruris. eMedicine from WebMD [Internet]. 2006 May [cited 2010 Jun 02];[about 11 p.] Available from: http://www.emedicine.com/DERM/ topic471.htm.
10. Masri-Fridling GD. Dermatophytosis of the feet. Dermatol Clin. 1996;14(1): 33-40.
11. Markova T. Clinical inquiries. What is the most effective treatment for tinea pedis (athlete's foot)? J Fam Pract. 2002;51(1):21-7.
12. Andrews MD, Burns M. Common tinea infections in children. Am Fam Physician. 2008;77(10):1415-20.
13. Evans EG, James IG, Seaman RA, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol. 1993;129 (4):437-442.
14. Merz Pharmaceuticals, LLC. Naftifine product monograph. 2010.
15. Monk JP, Brogden RN. Naftifine: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991;42(4):659-72.
16. Vago T, Baldi G, Columbo D, et al. Effects of naftifine, terbinafine, two allylamine antifungal drugs, on selected functions of polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1994;38(11):2605-11.
17. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehiclecontrolled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. Journal of Drugs in Dermatology. 2011; 10(11):1282-1288.
18. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehiclecontrolled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. Journal of Drugs in Dermatology. 2011;10(10):1142-1147.
19. Stein Gold LF, Parish LC, Vlahovic T, et al. Efficacy and safety of naftifine HCl gel 2% in the treatment of interdigital and moccasin-type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. Journal of Drugs in Dermatology. 2013, in press.
20. Escobar-Chavez JJ, Merino-Sanjuan V, Lopez-Cervantes M, et al. The tapestripping technique as a method for drug quantification in skin. Journal of Pharmaceutical Science. 2008;11(1):104-130.
21. Kyle AA, Dahl MV. Topical therapy for fungal infections. Am J Clin Dermatol. 2004;5(6):443-451.
22. Joseph WS. A closer look at topical for tinea infections. Podiatry Today. 2009;22(9):48-56.
23. Schmid D, Belser E, Liechti C, Zulli F. Skin rejuvenation with a biomimetic peptide designed to promote desquamation. SOFW-Journal. 2006;132(3):2-6.
24. Kosinski M, Joseph WS, Markinson B. Advances in the treatment of tinea pedis. Podiatry Management. 2007;229-38.
25. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008;12(2):51-58.
26. El-Mahrab RM, Kalia YN. New developments in topical antifungal therapy. Am J Drug Deliv. 2006;4(4):231-247.
27. Schafer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol. 2008;21(4):203-210.
28. Kagawa S. Comparative Clinical Trial of Naftifine and Clotrimazole in Tinea Pedum, Tinea Cruris, and Tinea Corporis. Mykosen. 1987;30(suppl1):63-69.
29. Naftifine Podiatric Study Group. Naftifine Cream 1% Versus Clotrimazole Cream 1% in Treatment of Tinea Pedis. J Am Podiatr Med Assoc. 1990;80(6):314-318.
30. Smith EB, Wiss K, Hanifin JM, et al. Comparison of Once-and Twice-Daily Naftifine Cream Regimens with Twice-Daily Clotrimazole in the Treatment of Tinea pedis. J Am Acad Dermatol. 1990;22:6(1):1116-1117.
31. Ablon G, Rosen T, Spedale J. Comparative Efficacy of Naftifine, Oxiconazole, and Terbinafine in Short-Term Treatment of Tinea Pedis. Int J Dermatol. 1996;35(8):591-593.
32. Dobson RL, Hickman JG, Landow RK, et al. Once-Daily Naftifine Cream 1% (Naftin) in the Treatment of Tinea Pedis. Clin Trials J. 1989;26(6):418-423.
33. Naftifine Gel Study Group. Naftifine Gel in the Treatment of Tinea Pedis: Two Double-Blind, multicenter studies. Cutis. 1991;48(1):85-88.
34. Schachner L, Bagatell F, Whittington C, Willis I, Sefton J, deGryse R. The Safety and Efficacy of Naftifine 1% in the Treatment of Tinea Pedis. Adv Ther. 1990;7(3):148-152.
35. Stoughton RB, Sefton J, Zeleznik L. In vitro and In Vivo Cutaneous Penetration of and Antifungal Activity of Naftifine. Cutis. 1989;44(4):333-335.